Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
19 Nov 2025 | Category: Technology
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin...
🔗 Read More at Original SourceRelated Articles
How Apple Mass Produces Titanium Watch Cases with 3D Printing Technology
Apple’s Watch Ultra 3 and titanium Series 11 cases are now made using large-scale 3D printing, replacing traditional machining. Here’s how the …
Who Is Abidur Chowdhury? Apple iPhone Air Designer Joins AI Startup
Apple iPhone Air design team member who was featured in the official launch video has reportedly left the US-based tech giant to …
Adidas Collaborates with Minecraft for an Exciting New Collection
We’re teaming up with adidas once again to bring you not just a new collection but also an immersive dynamic world for …